Myriad Genetics, Inc. (MYGN) Reports In-Line Q2 EPS; Issues FY12 Outlook
Tweet Send to a Friend
Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q2 EPS of $0.34, in-line with the analyst estimate of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
